Nanopath, a diagnostics company based in Cambridge, Massachusetts, closed a $25m Series B round, it announced on 10 November 2026. The total includes $2m of non-dilutive grant funding, so the equity portion was about $23m.
Norwest and SV Health Investors' MedTech Convergence Fund co-led the round, and the Labcorp Venture Fund took part as a strategic investor. New and existing investors Elderberry Ventures, GingerBread Capital and Alumni Ventures also invested. No valuation was disclosed.
Founded in 2020, Nanopath said it has now raised more than $46m. It describes itself as a women-led company focused first on women's health, and its stated aim is to make complex diagnostic testing available in clinics rather than only in centralised laboratories.
“This funding brings us closer to the next and most important step – translating that innovation into meaningful clinical impact.”Alison Burklund, Co-Founder and Co-CEO, Nanopath
What Nanopath does
Nanopath has built a clinical diagnostics platform based on plasmonic biosensing, an optical technique. The company says it can detect molecular targets without amplifying DNA or RNA, the step that PCR tests depend on, which would allow laboratory-quality molecular results at the point of care.
Its first product is a test for vaginitis designed to return results in about 15 minutes during a single clinic visit, rather than sending samples to an outside laboratory. Femtech Insider reported that the company is also exploring tests for urinary tract infections and sexually transmitted infections.
The vaginitis test is still in development and has not been cleared or approved by the US Food and Drug Administration. The company is based at The Engine, the MIT-founded facility for hard-technology start-ups, and is led by co-founders and co-chief executives Alison Burklund and Amogha Tadimety.
What the money is for
Nanopath said the funding would cover manufacturing scale-up and the start of an FDA 510(k) clinical study for the vaginitis test, as well as hiring in clinical and commercial roles before a possible launch. Femtech Insider reported that the study is planned for 2028 and is expected to enrol about 1,500 patients at 10 to 15 sites.
As part of the round, Catherine Kiani, managing partner at Elderberry Ventures, and Mindy Nye, a vice president at Labcorp Diagnostics, joined the company's board as observers. Nanopath said the financing would also support a possible expansion of its pipeline into urinary tract and sexually transmitted infections.
The funding so far
Norwest and the MedTech Convergence Fund also co-led Nanopath's $10m Series A in August 2022, according to Femtech Insider, with GingerBread Capital among the other investors. At that time the company said it was targeting pelvic and gynaecologic infections and had run pilot clinical work with hospital systems in New England.
Jeff Crowe, senior managing partner at Norwest, said the firm would keep supporting the company at what he called a key point in its development, and said the technology could change how molecular diagnostics are done. Tadimety described Nanopath as focused on women's healthcare and said the company was moving into its next phase of growth.
Company website: nanopath.com
